Glibenclamide in cerebral ischemia and stroke.
Glibenclamide in cerebral ischemia and stroke.
复制标题
DOI：
10.1007/s12028-013-9923-1
复制
发表时间：
2014-04
影响因子：
3.5
通讯作者：
Gerzanich V
中科院分区：
文献类型：
--
作者：
Simard JM;Sheth KN;Kimberly WT;Stern BJ;del Zoppo GJ;Jacobson S;Gerzanich V
The sulfonylurea receptor 1 (Sur1)–transient receptor potential 4 (Trpm4) channel is an important molecular element in focal cerebral ischemia. The channel is upregulated in all cells of the neurovascular unit following ischemia, and is linked to microvascular dysfunction that manifests as edema formation and secondary hemorrhage, which cause brain swelling. Activation of the channel is a major molecular mechanism of cytotoxic edema and “accidental necrotic cell death.” Blockade of Sur1 using glibenclamide has been studied in different types of rat models of stroke: (i) in conventional non-lethal models (thromboembolic, 1–2 h temporary, or permanent middle cerebral artery occlusion), glibenclamide reduces brain swelling and infarct volume and improves neurological function; (ii) in lethal models of malignant cerebral edema, glibenclamide reduces edema, brain swelling, and mortality; (iii) in models with rtPA, glibenclamide reduces swelling, hemorrhagic transformation, and death. Retrospective studies of diabetic patients who present with stroke have shown that those whose diabetes is managed with a sulfonylurea drug and who are maintained on the sulfonylurea drug during hospitalization for stroke have better outcomes at discharge and are less likely to suffer hemorrhagic transformation. Here, we provide a comprehensive review of the basic science, preclinical experiments, and retrospective clinical studies on glibenclamide in focal cerebral ischemia and stroke. We also compare the preclinical work in stroke models to the updated recommendations of the Stroke Therapy Academic Industry Roundtable (STAIR). The findings reviewed here provide a strong foundation for a translational research program to study glibenclamide in patients with ischemic stroke.
登录
查看更多内容
DOI：
10.1186/2040-7378-2-2
发表时间：
2010-01-21
期刊：
Experimental & translational stroke medicine
影响因子：
--
作者：
Durukan A;Tatlisumak T
通讯作者：
Tatlisumak T
影响因子：
48
作者：
Gray, Christopher S.;Hildreth, Anthony J.;Alberti, K. George M. M.
通讯作者：
Alberti, K. George M. M.
影响因子：
8.8
作者：
Figura, M.;Chilton, L.;Tibbles, L. A.
通讯作者：
Tibbles, L. A.
影响因子：
8.3
作者：
Fisher M;Feuerstein G;Howells DW;Hurn PD;Kent TA;Savitz SI;Lo EH;STAIR Group
通讯作者：
STAIR Group
影响因子：
--
作者：
Hacke, W;Schwab, S;vonKummer, R
通讯作者：
vonKummer, R